PYC Therapeutics (ASX:PYC) Releases Q2 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) updates shareholders on significant clinical progress and a strong financial position in Q2 2025.
Category: ASX-PYC
PYC Therapeutics Limited
PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.
PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.
PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.